For patients with HAE nC1-INH, it was found that the median (range) duration of attacks significantly decreased to 0.29 days (0.02–4.00) following treatment initiation, compared to 1.00 days (0.00–7.00) before treatment (p = 0.001, Table 3). This evidence concerns the gene COL18A1 and hereditary angioedema.